Journal Drug Safety

Adopting STOPP/START Criteria Version 3 in Clinical Practice: A Q&A Guide for Healthcare Professionals

C Lunghi , M Domenicali , S Vertullo , ... , E Poluzzi

10.1007/s40264-024-01453-1

Pregnancy Outcomes in Patients Treated with Upadacitinib: Analysis of Data from Clinical Trials and Postmarketing Reports

U Mahadevan , G Levy , L Gensler , ... , AR Scialli

10.1007/s40264-024-01454-0

The STAR Compass to Guide Future Pharmacovigilance Based on a 10-Year Review of the Strengthened EU System

P Bahri , G Genov , P Arlett , ... , SMJM Straus

10.1007/s40264-024-01451-3

Enhanced Safety Surveillance of GSK's Inactivated Quadrivalent Seasonal Influenza Vaccine in Belgium, Germany, and Spain During the 2022/2023 Influenza Season.

IS de la Cueva , JE Gerber , A Hastie , ... , H Alsdurf

10.1007/s40264-024-01456-y

Use of the Sentinel System to Examine Medical Product Use and Outcomes During Pregnancy.

JG Lyons , MU Shinde , JC Maro , ... , S Toh

10.1007/s40264-024-01447-z

The PrescIT platform: An interoperable Clinical Decision Support System for ePrescription to Prevent Adverse Drug Reactions and Drug-Drug Interactions

P Natsiavas , G Nikolaidis , J Pliatsika , ... , I Kompatsiaris

10.1007/s40264-024-01455-z

A Calculated Risk: Evaluation of QTc Drug-Drug Interaction (DDI) Clinical Decision Support (CDS) Alerts and Performance of the Tisdale Risk Score Calculator.

RL Wasserman , DL Seger , MG Amato , ... , DW Bates

10.1007/s40264-024-01466-w

Author's Reply to Avó-Baião et al.'s Comment on "Maternal and Early-Life Exposure to Antibiotics and the Risk of Autism and Attention-Deficit Hyperactivity Disorder in Childhood: A Swedish Population-Based Cohort Study".

N Brusselaers

10.1007/s40264-024-01463-z

Comment on: "Maternal and Early-Life Exposure to Antibiotics and the Risk of Autism and Attention-Deficit Hyperactivity Disorder in Childhood: A Swedish Population-Based Cohort Study".

R Avó-Baião , R Vareda , A Lopes

10.1007/s40264-024-01464-y

A Systematic Overview of Contraindications and Special Warnings for Biologic and Targeted Synthetic Disease Modifying Antirheumatic Drugs: Establishing a Framework to Create a "Safety Checklist".

L Skaarup , E Ingrid , A Sepriano , ... , TW Kragstrup

10.1007/s40264-024-01461-1